RMD ResMed Inc.

ResMed Announces Participation in the UBS Global Healthcare Conference

ResMed Announces Participation in the UBS Global Healthcare Conference

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA.

More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investors

 For media

+1 858.836.5000 +1 619.510.1281
 



EN
05/11/2024

Underlying

RMDResMed Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 202...

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin ...

April 23, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Resmed Names Salli Schwartz as Chief Investor Relations Officer Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairm...

April 21, 2025 1 EN
Free Trial
RMD RESMED INC.

ResMed Inc: 1 director

A director at ResMed Inc sold 2,000 shares at 219.740USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

04/05/25 April 5, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, ...

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosis SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, ™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified,...

April 3, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location: •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PD...

April 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch